Advertisement
MEOBF vs MESO
To understand the difference between Mesoblast Ltd (MEOBF) vs. Mesoblast Ltd - ADR (MESO) it is enough to know the definitions of ADR
ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MEOBF’s FA Score shows that 0 FA rating(s) are green whileMESO’s FA Score has 0 green FA rating(s).
- MEOBF’s FA Score: 0 green, 5 red.
- MESO’s FA Score: 0 green, 5 red.
Price Growth
MEOBF (@Biotechnology) experienced а 0.00% price change this week, while MESO (@Biotechnology) price change was -2.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.02%. For the same industry, the average monthly price growth was +7.66%, and the average quarterly price growth was -1.31%.
Reported Earning Dates
MEOBF is expected to report earnings on Aug 27, 2025.
MESO is expected to report earnings on Aug 27, 2025.
Industries' Descriptions
@Biotechnology (+5.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| MEOBF | MESO | MEOBF / MESO | |
| Capitalization | 1.38B | 1.38B | 100% |
| EBITDA | -77.78M | -77.78M | 100% |
| Gain YTD | -35.118 | -43.131 | 81% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 5.67M | 5.67M | 100% |
| Total Cash | 37.7M | 37.7M | 100% |
| Total Debt | 126M | 126M | 100% |
MEOBF | MESO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 97 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 44 | 50 | |
P/E GROWTH RATING 1..100 | 53 | 97 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MEOBF's Valuation (88) in the null industry is in the same range as MESO (88) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.
MEOBF's Profit vs Risk Rating (100) in the null industry is in the same range as MESO (100) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.
MEOBF's SMR Rating (100) in the null industry is in the same range as MESO (100) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.
MEOBF's Price Growth Rating (44) in the null industry is in the same range as MESO (50) in the Biotechnology industry. This means that MEOBF’s stock grew similarly to MESO’s over the last 12 months.
MEOBF's P/E Growth Rating (53) in the null industry is somewhat better than the same rating for MESO (97) in the Biotechnology industry. This means that MEOBF’s stock grew somewhat faster than MESO’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
Advertisement
MEOBF and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.
| Ticker / NAME | Correlation To MEOBF | 1D Price Change % | ||
|---|---|---|---|---|
| MEOBF | 100% | N/A | ||
| SPHDF - MEOBF | 50% Loosely correlated | N/A | ||
| AVTX - MEOBF | 46% Loosely correlated | -7.56% | ||
| COGT - MEOBF | 39% Loosely correlated | -6.21% | ||
| MESO - MEOBF | 26% Poorly correlated | -2.43% | ||
| KROS - MEOBF | 26% Poorly correlated | -0.71% | ||
More | ||||